Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Operations (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Cash from Operations for 10 consecutive years, with 25389000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 34.73% to 25389000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 115675000.0 through Dec 2025, down 1.58% year-over-year, with the annual reading at 115675000.0 for FY2025, 1.58% down from the prior year.
  • Cash from Operations for Q4 2025 was 25389000.0 at Rhythm Pharmaceuticals, up from 26622000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 18845000.0 in Q4 2024, with the low at 53632000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 34257100.0, with a median of 33765500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations crashed 59.95% in 2022, then soared 37.75% in 2023.
  • Over 5 years, Cash from Operations stood at 40472000.0 in 2021, then grew by 15.99% to 34000000.0 in 2022, then rose by 13.58% to 29383000.0 in 2023, then skyrocketed by 35.86% to 18845000.0 in 2024, then plummeted by 34.73% to 25389000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 25389000.0, 26622000.0, and 23313000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.